John Goldberg
Chief Tech/Sci/R&D Officer at RAFAEL HOLDINGS, INC.
Net worth: 344 $ as of 31/12/2023
Profile
John M.
Goldberg is currently the Chief Medical Officer at Rafael Holdings, Inc. Prior to this, he was the Chief Medical Officer at Oncorus, Inc. from 2018 to 2023.
He also held the position of Senior Director-Medical at H3 Biomedicine, Inc. and Head-Clinical Development at Agenus, Inc. Dr. Goldberg received his undergraduate degree from The University of Chicago and his doctorate from the University of Massachusetts Medical School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ONCORUS, INC.
0.01% | 31/03/2023 | 2,730 ( 0.01% ) | 344 $ | 31/12/2023 |
John Goldberg active positions
| Companies | Position | Start |
|---|---|---|
| RAFAEL HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 20/11/2023 |
Former positions of John Goldberg
| Companies | Position | End |
|---|---|---|
| ONCORUS, INC. | Chief Tech/Sci/R&D Officer | 30/06/2023 |
| AGENUS INC. | Chief Tech/Sci/R&D Officer | - |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | - |
Training of John Goldberg
| The University of Chicago | Undergraduate Degree |
| UMass Chan Medical School | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| AGENUS INC. | Health Technology |
| ONCORUS, INC. | Health Technology |
| RAFAEL HOLDINGS, INC. | Finance |
| Private companies | 1 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Stock Market
- Insiders
- John Goldberg
